PL2192907T3 - Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych - Google Patents

Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych

Info

Publication number
PL2192907T3
PL2192907T3 PL08789793T PL08789793T PL2192907T3 PL 2192907 T3 PL2192907 T3 PL 2192907T3 PL 08789793 T PL08789793 T PL 08789793T PL 08789793 T PL08789793 T PL 08789793T PL 2192907 T3 PL2192907 T3 PL 2192907T3
Authority
PL
Poland
Prior art keywords
erythropoietin
therapeutic applications
fibronectin
compositions
fibronectin compositions
Prior art date
Application number
PL08789793T
Other languages
English (en)
Polish (pl)
Inventor
Saher Hamed
Original Assignee
Remedor Biomed Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedor Biomed Ltd. filed Critical Remedor Biomed Ltd.
Publication of PL2192907T3 publication Critical patent/PL2192907T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PL08789793T 2007-08-16 2008-08-13 Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych PL2192907T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93549707P 2007-08-16 2007-08-16
US6431108P 2008-02-27 2008-02-27
PCT/IL2008/001119 WO2009022338A2 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
EP08789793.0A EP2192907B1 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic applications

Publications (1)

Publication Number Publication Date
PL2192907T3 true PL2192907T3 (pl) 2018-10-31

Family

ID=40351263

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08789793T PL2192907T3 (pl) 2007-08-16 2008-08-13 Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych

Country Status (5)

Country Link
US (7) US20110123481A1 (enExample)
EP (1) EP2192907B1 (enExample)
JP (1) JP5869219B2 (enExample)
PL (1) PL2192907T3 (enExample)
WO (1) WO2009022338A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564735B2 (ja) * 2009-07-31 2014-08-06 国立大学法人 熊本大学 アクアポリン３の発現調節剤
BR112012021179A2 (pt) * 2010-02-23 2015-09-15 Sebana Medical Ltd método para aprimorar a sobrevivência da gordura adiposa em um paciente que necessite da mesma, uso de eritropoietina e composição farmacêutica
KR20150133222A (ko) * 2013-03-13 2015-11-27 스테메트릭스, 인코포레이티드. 피부 조성물 및 피부 조성물의 용도
KR102240373B1 (ko) * 2013-05-07 2021-04-13 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 입자상 탈세포화 조직의 제조방법
EP3344229B1 (en) 2015-09-04 2023-11-01 Remedor Biomed Ltd. Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations
KR20180093932A (ko) * 2015-12-16 2018-08-22 다이이찌 산쿄 가부시키가이샤 창상 치료제
CA3011208A1 (en) 2016-01-15 2017-07-20 Universitat Hamburg Methods for the production of rhamnosylated flavonoids
CN109071482A (zh) 2016-01-15 2018-12-21 汉堡大学 携有o-鼠李糖基残基的类黄酮型化合物
CA3028429A1 (en) * 2016-06-21 2017-12-28 The Regents Of The University Of California Wound healing using braf inhibitors
ES2952448T3 (es) 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
JP7605576B2 (ja) * 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
JP2020070270A (ja) * 2018-11-01 2020-05-07 御木本製薬株式会社 フィブロネクチン遺伝子発現促進剤
CN116531306A (zh) * 2023-02-27 2023-08-04 珠海盈盛联科生物科技有限公司 含重组人纤连蛋白具有修复功效组合物、制备方法及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5124155A (en) 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
GB9315810D0 (en) * 1993-07-30 1993-09-15 Univ London Stabilised materials
US7112320B1 (en) * 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6007802A (en) 1996-03-27 1999-12-28 The Procter & Gamble Co. Conditioning shampoo composition
EP0992232A4 (en) * 1997-03-11 2003-01-02 Pola Chem Ind Inc TESTING METHODS OF SKIN CARE AGENTS AND EXTERNAL SKIN CARE PRODUCTS MANUFACTURING METHOD
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6194378B1 (en) * 1998-02-18 2001-02-27 The Research Foundation Of State University Of New York Fibronectin peptides-based extracellular matrix for wound healing
GB9804720D0 (en) 1998-03-05 1998-04-29 Unilever Plc Shampoo compositions
AU5390699A (en) 1998-07-24 2000-02-14 Pharmacal Biotechnologies, Inc. Osseous tissue reconstruction system and method
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6960173B2 (en) 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US6913762B2 (en) 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
AU2003219916A1 (en) 2002-02-22 2003-09-09 University Of Washington Bioengineered tissue substitutes
JPWO2003103703A1 (ja) 2002-06-06 2005-10-06 中外製薬株式会社 骨代謝疾患治療剤
ES2422881T3 (es) 2002-06-20 2013-09-16 Augustinus Bader Uso de eritropoyetina para la regeneración de tejido in vivo
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10303584A1 (de) 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
AU2004214932B2 (en) * 2003-02-24 2009-12-03 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and use thereof
US7459152B2 (en) 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
EP1673102A1 (en) * 2003-10-17 2006-06-28 Crucell Holland B.V. Treatment and prevention of decubitus
WO2005046746A2 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
ES2346226T3 (es) 2003-12-30 2010-10-13 Augustinus Bader Uso de la eritropoyetina para la regeneracion de tejido hepatico.
EP1550715A1 (de) 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
WO2005070451A1 (en) * 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20060228416A1 (en) * 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
WO2007055760A2 (en) 2005-10-31 2007-05-18 Essential Skincare, Llc Protein composition for promoting wound healing and skin regeneration
WO2007087402A2 (en) 2006-01-24 2007-08-02 Brown University Cell aggregation and encapsulation device and method
DK2656832T3 (en) * 2006-05-11 2019-04-08 Regenics As Compositions for use in wound healing
JP5411703B2 (ja) * 2006-11-09 2014-02-12 アルコン リサーチ， リミテッド 薬物送達のための水不溶性ポリマーマトリクス
US7717855B2 (en) * 2006-12-06 2010-05-18 The Hospital For Sick Children System for performing remote ischemic preconditioning
WO2008134712A2 (en) * 2007-04-30 2008-11-06 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
BRPI0812718A2 (pt) 2007-06-19 2014-12-23 Baxter Int Métodos para modificar a liberação de uma proteína do fator de crescimento derivado de plaqueta, para modificar a liberação de um fator de crescimento derivado de plaqueta, para a liberação de uma proteína do fator de crescimento derivado de plaqueta e para tratar um paciente que sobre de um distúrbio ou doença, kit, e, uso de um selante de fibrina
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US20090045968A1 (en) 2007-08-16 2009-02-19 Optimal Innovations Inc. Utility Outlets Capable of Presenting Images
US9101586B2 (en) 2007-12-28 2015-08-11 Augustine Bader Topical application and formulation of erythropoietin for skin wound healing
JP5829400B2 (ja) 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物

Also Published As

Publication number Publication date
US20110123481A1 (en) 2011-05-26
EP2192907A4 (en) 2011-07-06
JP2010536745A (ja) 2010-12-02
US20220000987A1 (en) 2022-01-06
WO2009022338A2 (en) 2009-02-19
US20190192637A1 (en) 2019-06-27
US20170056480A1 (en) 2017-03-02
EP2192907B1 (en) 2018-04-18
US20160030525A1 (en) 2016-02-04
EP2192907A2 (en) 2010-06-09
US20190117740A1 (en) 2019-04-25
US20140154205A1 (en) 2014-06-05
JP5869219B2 (ja) 2016-02-24
US10792338B2 (en) 2020-10-06
WO2009022338A3 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
HUS1800007I1 (hu) Gyógyászati készítmény
IL201891A0 (en) Novel pharmaceutical composition
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
GB0700534D0 (en) Composition
ZA201001300B (en) Antigen-asjuvant compositions and methods
ZA200905224B (en) Pharmaceutical composition
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0717376D0 (en) Composition and manufacture thereof
IL232923A0 (en) Enhanced erythropoietin
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
GB0809912D0 (en) Novel compositions and uses thereof
GB0715428D0 (en) Compositions and uses thereof
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0701170D0 (en) Compositions and uses thereof
IL205975A0 (en) Pharmaceutical composition
GB0701171D0 (en) Compositions and uses thereof
IL205931A0 (en) Pharmaceutical composition
GB0725264D0 (en) Compositions and uses thereof
GB0725266D0 (en) Novel esters and compositions and uses thereof
IL203964A (en) Drugs of erythropoietin and fibronectin for medicinal and cosmetic uses
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB0909792D0 (en) Composition and uses thereof
GB0701713D0 (en) Cosmetic composition